Orforglipron vs Semaglutide vs Tirzepatide: Which Should You Actually Be On in 2026?

Until 2026, choosing a GLP-1 was mostly a two-way question: semaglutide or tirzepatide. The April approval of orforglipron added a third option that is different in kind rather than degree — an oral small molecule with no dosing restrictions.

The temptation is to rank them by weight loss and pick the top one. That is the wrong method, because the highest number belongs to a drug many people cannot get, cannot afford, or will not stay on. This is a comparison built around the decision you are actually making.

The Comparison at a Glance

	Orforglipron (Foundayo)	Semaglutide (Wegovy/Ozempic)	Tirzepatide (Zepbound/Mounjaro)
Mean weight loss	~12.4%	~15-17% (injectable)	~21%
Molecule type	Small molecule	Peptide	Peptide
Receptor targets	GLP-1	GLP-1	GLP-1 + GIP
Administration	Daily pill, any time, no restrictions	Weekly injection (or daily pill with strict protocol)	Weekly injection
Notable access point	$50/mo for eligible Medicare Part D	Widest insurance coverage; longest track record	Strongest efficacy; coverage varies

Efficacy: Real, But Not the Only Axis

On weight loss alone the ordering is clear: tirzepatide, then semaglutide, then orforglipron. Tirzepatide's advantage is generally attributed to its dual action — it engages the GIP receptor in addition to GLP-1, which appears to produce additive metabolic effects.

Two qualifications matter. First, these are trial averages; individual response varies widely, and some people lose more on semaglutide than others do on tirzepatide. Second, trial averages come from patients supported by study infrastructure — regular contact, dose titration, adherence monitoring. Real-world results are typically lower across all three.

The number that matters is not peak efficacy but expected efficacy multiplied by the probability you are still taking it in a year. Discontinuation rates in this class are substantial, and cost and side effects are the leading drivers.

Dosing Burden: The Underrated Variable

Weekly injection (semaglutide, tirzepatide) means fifty-two administrations a year and a needle. For most people the needle is a smaller obstacle than anticipated. For a genuine minority it is a hard barrier, and clinicians consistently underestimate how many patients quietly never start because of it.

Oral semaglutide removes the needle but imposes a strict protocol: empty stomach, up to four ounces of plain water, thirty minutes before anything else. Adherence in practice is meaningfully worse than the trial data implies.

Orforglipron is a daily pill with no restrictions at all. But daily is not automatically easier than weekly — it is 365 opportunities to forget rather than 52. Some people are better served by one deliberate weekly event.

Side Effects

All three share the GLP-1 class profile: nausea, vomiting, diarrhea or constipation, reduced appetite, abdominal discomfort — worst during escalation, improving with slower titration. Class warnings around thyroid C-cell tumors, pancreatitis, and gallbladder events apply throughout.

Tirzepatide's higher efficacy comes with somewhat more GI burden for many patients, though tolerability is highly individual.

Lean mass loss deserves separate mention because it applies to all three and is widely under-discussed. Across GLP-1 therapy, a substantial fraction of weight lost can come from lean tissue rather than fat. This is why resistance training and adequate protein are not optional. It is also the problem the emerging bimagrumab combinations are designed to solve — in Phase 2, adding bimagrumab to semaglutide produced roughly 22% weight loss with about 92% of it from fat mass.

Cost and Access

This is where the ranking often inverts. The strongest drug is irrelevant if it is unaffordable.

A significant change: the compounded route is closing. The shortage exemption that made $200-400/month compounded semaglutide and tirzepatide possible no longer applies, and the FDA has proposed removing both from the 503B bulks list with a decision expected in the second half of 2026. If your plan depends on compounded pricing, it needs revisiting.

Also worth correcting: semaglutide's 2026 patent expiries were in India, China, Canada, Brazil, and Turkey — not the United States. A US generic is not expected until roughly 2033-2036.

Practically, orforglipron's $50 Medicare Part D access is the most consequential affordability development of 2026 for a population that was largely locked out of this category.

A Decision Framework

Rather than ranking, match to situation:

• You need maximum weight loss and can access it: Tirzepatide. It leads on efficacy and the margin over semaglutide is clinically real.
• You have Medicare Part D: Start the orforglipron conversation. $50/month against $900+ changes the calculus regardless of the efficacy gap.
• Needles are a genuine barrier: Orforglipron, without hesitation. A 12.4% drug you take beats a 21% drug you decline.
• You tried oral semaglutide and could not sustain the protocol: Orforglipron solves precisely that problem.
• You have cardiovascular disease: Semaglutide has the deepest cardiovascular outcomes evidence. Raise this specifically with your prescriber.
• You are on compounded product now: Your immediate task is not choosing between these three — it is establishing what you can obtain legally and afford six months from now, before your supply is interrupted.
• You can wait 12-24 months and want the strongest option: CagriSema (~22.7%, FDA decision expected late 2026) and retatrutide (~24%, BLA planned Q1 2027) are both stronger. Waiting is only reasonable if your health can tolerate the delay — for many patients with established metabolic disease, it cannot.

The Short Version

Tirzepatide wins on efficacy. Semaglutide has the longest track record and the best cardiovascular data. Orforglipron wins on access and convenience, which for a large number of people is what actually determines whether treatment works — because the drug you stay on outperforms the drug you quit.

This is a conversation to have with a prescriber who knows your history, your coverage, and your comorbidities. Our directory lists providers by state and by therapies offered if you need somewhere to start.